drugset
drugset / Trial / NCT01854489

Effects of Rifampicin on the Pharmacokinetics and Pharmacodynamics of Sublingual and Intravenous Buprenorphine

NCT01854489 ↗

Phase 4 Completed 12 enrolled Turku University Hospital
RandomizedCrossoverSingle-blindBasic science

Summary

This study is aimed to examine the possible interactions of sublingual and intravenous buprenorphine with rifampicin.

Timeline

Start
2013-04
Primary completion
2014-11
Completion
2014-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Buprenorphine Other / unclassified 0.4 mg Intravenous
Comparator Buprenorphine Other / unclassified 0.6 mg Intravenous
Comparator Rifampin Small molecule 600 mg Oral

Indications

No indication recorded.